<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	
	xmlns:georss="http://www.georss.org/georss"
	xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#"
	>

<channel>
	<title>Necessary conditions &#8211; Spress</title>
	<atom:link href="https://en.spress.net/tag/necessary-conditions/feed/" rel="self" type="application/rss+xml" />
	<link>https://en.spress.net</link>
	<description>Spress is a general newspaper in English which is updated 24 hours a day.</description>
	<lastBuildDate>Wed, 19 May 2021 03:19:11 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	
<site xmlns="com-wordpress:feed-additions:1">191965906</site>	<item>
		<title>Japan plans to produce vaccines domestically</title>
		<link>https://en.spress.net/japan-plans-to-produce-vaccines-domestically/</link>
		
		<dc:creator><![CDATA[Hoàng Nguyễn/VOV-Tokyo]]></dc:creator>
		<pubDate>Wed, 19 May 2021 03:19:11 +0000</pubDate>
				<category><![CDATA[Tech]]></category>
		<category><![CDATA[Ability to provide]]></category>
		<category><![CDATA[Antibody]]></category>
		<category><![CDATA[clinical]]></category>
		<category><![CDATA[Domestic]]></category>
		<category><![CDATA[domestically]]></category>
		<category><![CDATA[Enough numbers]]></category>
		<category><![CDATA[Green light on]]></category>
		<category><![CDATA[hope]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[Manufacturing]]></category>
		<category><![CDATA[Medicine]]></category>
		<category><![CDATA[Moderna]]></category>
		<category><![CDATA[Necessary conditions]]></category>
		<category><![CDATA[Plan]]></category>
		<category><![CDATA[plans]]></category>
		<category><![CDATA[produce]]></category>
		<category><![CDATA[Producer]]></category>
		<category><![CDATA[safety]]></category>
		<category><![CDATA[SARS COV 2]]></category>
		<category><![CDATA[Takeda Pharmaceutical Co]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Vaccines against Covid 19]]></category>
		<category><![CDATA[welfare]]></category>
		<guid isPermaLink="false">https://en.spress.net/japan-plans-to-produce-vaccines-domestically/</guid>

					<description><![CDATA[On May 10, Japanese drug manufacturer Shionogi announced that it plans to supply a Covid-19 vaccine this year, if necessary conditions are met. Accordingly, this will be the first domestically produced vaccine to help Japan prevent SARS-CoV-2 virus. Currently, with the Covid-19 vaccine developed by the US pharmaceutical giant Pfizer and other manufacturers already in [&#8230;]]]></description>
										<content:encoded><![CDATA[<p><strong>On May 10, Japanese drug manufacturer Shionogi announced that it plans to supply a Covid-19 vaccine this year, if necessary conditions are met.</strong><br />
<span id="more-16011"></span> Accordingly, this will be the first domestically produced vaccine to help Japan prevent SARS-CoV-2 virus. Currently, with the Covid-19 vaccine developed by the US pharmaceutical giant Pfizer and other manufacturers already in use around the world, it is important to ensure enough participants for the trials. Large-scale clinical practice is becoming a barrier for latecomers like Shionogi.</p>
<p> <img decoding="async" loading="lazy" src="https://photo-baomoi.zadn.vn/w700_r1/2021_05_11_65_29158779/9cb3dd3fc37d2a23736c.jpg" width="625" height="351"> <em> Japan plans to produce the vaccine domestically. Illustration: CNN</em> Shionogi is currently in discussions with the Ministry of Health, Labor and Welfare about a framework that would allow the efficacy and safety of vaccines to be assessed even with small-scale trials. This manufacturer hopes to contribute to the early prevention of the Covid-19 pandemic by focusing on investment and management of resources. In addition, the company has also completed a production line capable of supplying 10 million people a year with vaccines and plans to increase capacity further. Regarding Moderna&#8217;s vaccine approval process, on May 10, the pharmaceutical company Takeda said that clinical trials have confirmed that Moderna&#8217;s vaccine has helped increase antibodies in vaccinated people. The Japanese Ministry of Health, Labor and Welfare will evaluate and make a decision on whether to give the vaccine a &#8220;green light&#8221; as early as May 20.</p>
]]></content:encoded>
					
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">16011</post-id>	</item>
	</channel>
</rss>